Clinical Trials Sponsored by Immunotherapy Foundation

Total 15734 results

Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
JANSSEN Alzheimer Immunotherapy Research & Development...

Terminated

AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Alzheimer's Disease

United States, Korea, Republic of
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Netherlands Working Group on Immunotherapy of Oncology

Completed

Rotating Pazopanib and Everolimus to Avoid Resistance (ROPETAR)

Clear Cell Renal Carcinoma

Netherlands
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Japan
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Terminated

Retrieval of Patient Information After Discontinuation (RAPID)

Alzheimer's Disease
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease (ACCTION)

Alzheimer's Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease (SUMMIT AD)

Alzheimer's Disease

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Terminated

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

Alzheimer's Disease

United States, Germany, Canada, Austria
JANSSEN Alzheimer Immunotherapy Research & Development...
Pfizer

Completed

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

Alzheimer's Disease

United States
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb

Completed

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Melanoma

United States
Parker Institute for Cancer Immunotherapy
Seres Therapeutics, Inc.

Completed

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention (MCGRAW)

Metastatic Melanoma

United States
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy

Recruiting

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | CD20 Positive | Refractory Mantle Cell Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory... and other conditions

United States
Pfizer
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC

Completed

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
University of Pennsylvania
Parker Institute for Cancer Immunotherapy; Tmunity Therapeutics

Terminated

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

Melanoma | Multiple Myeloma | Myxoid/Round Cell Liposarcoma | Synovial Sarcoma

United States
University of California, San Francisco
Parker Institute for Cancer Immunotherapy; The V Foundation; Alliance for Cancer...

Recruiting

Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018)

Diffuse Midline Glioma, H3 K27M-Mutant

United States
Herlev and Gentofte Hospital
Danish Cancer Society; Danish Cancer Research Foundation; DCCC ctDNA Research... and other collaborators

Active, not recruiting

ctDNA for Early Detection of Recurrence in Melanoma

Melanoma

Denmark
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
Centre Leon Berard
French Immunotherapy Intergroup; SCAPP (Sub-Cutaneous Administration Proleukin...

Completed

Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis

Metastatic Renal Cell Carcinoma

France
Hadassah Medical Organization
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)

Withdrawn

Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

Metastatic Solid Tumors

Israel
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network (CITN)

Terminated

NT-I7 for Kaposi Sarcoma in Patients With or Without HIV

HIV Infection | Kaposi Sarcoma | AIDS-Related Kaposi Sarcoma

United States
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC; Parker Institute for Cancer Immunotherapy

Recruiting

Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

Advanced Sarcoma

United States
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City

Completed

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Advanced Metastatic Cancer | Advanced Prostate Cancer

United States
JANSSEN Alzheimer Immunotherapy Research & Development...
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Randomized Safety, Tolerability and Pilot Efficacy of AN-1792 in Alzheimer's Disease

Alzheimer's Disease

United States
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City; Apexigen, Inc.

Completed

Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Metastatic Pancreatic Adenocarcinoma

United States
Fundacion Miguel Servet
Hospital Universitario Getafe; Matia Foundation

Unknown

Impact of a Multicomponent Exercise Program on Functional Capacity in Frail Aged Participants With Cognitive Decline

Cognitive Impairment | Frail Elderly Syndrome

Spain
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
Netherlands Working Group on Immunotherapy of Oncology
Hoffmann-La Roche; Amsterdam UMC, location VUmc; The Netherlands Cancer Institute

Terminated

Vemurafenib Plus Cobimetinib in Metastatic Melanoma (REPOSIT)

Metastatic Melanoma

Netherlands
University Children's Hospital Basel
Swiss National Science Foundation; Fondation Botnar

Completed

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis (D2OBREATH)

De Novo Lipogenesis (DNL)

Switzerland
GOG Foundation
Intuitive Foundation

Recruiting

A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer (ROCC)

Cervical Cancer

United States, Canada
Foundation Fader
AB Foundation

Terminated

Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony

Cutaneous Leishmaniasis

Bolivia
University Hospital, Geneva
Fondation Privée des HUG; IF International Foundation

Not yet recruiting

Evaluation of a New Recovery-oriented Model of Psychiatric Inpatient Care

Recovery | Psychiatric Hospitalization | Coercion

Switzerland
Fondation Ophtalmologique Adolphe de Rothschild
Foundation Jacques and Gloria Gossweiler

Terminated

Finger Individuation Training With a Training Device Versus Conventional Rehabilitation for Writer's Cramp (FIDEX)

Dystonic Disorders

France
Pontificia Universidad Catolica de Chile
Millennium Institute on Immunology and Immunotherapy; Comisión Nacional de...

Completed

A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV (EVA-VRS01)

Respiratory Syncytial Virus Infections

Chile
Barcelonabeta Brain Research Center, Pasqual Maragall...
Fundacion SARquavitae

Completed

Experimental Study to Validate the "Therapeutic Game" CONEM-BETA

Dementia | Alzheimer's Disease

Spain
TargetCancer Foundation
Foundation Medicine

Recruiting

TCF-001 TRACK (Target Rare Cancer Knowledge) Study (TRACK)

Cholangiocarcinoma | Cancer of Unknown Primary Site | Rare Cancers

United States
University Hospital, Basel, Switzerland
Swiss Heart Foundation; Fondation Machaon, Switzerland, Genf; Foundation for...

Recruiting

Colchicine After Electrocardioversion for Atrial Fibrillation (COLECTRO-AF)

Atrial Fibrillation | Cardiac Arrhythmia

Switzerland
University Children's Hospital Basel
Swiss National Science Foundation; Fondation Botnar (Switzerland)

Recruiting

Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry in Children and Adolescents (EBECA)

Type 1 Diabetes | Neurological Disorders | Respiratory Diseases

Switzerland
Foundation for Science, Health and Education, Spain
Fondation Daniel & Nina Carasso

Completed

The Program SI! for Cardiovascular Health Promotion at Elementary School (PSIE)

Cardiovascular Disease

Spain
Foundation CPCT
Hartwig Medical Foundation

Active, not recruiting

CPCT-02 Biopsy Protocol (CPCT-02)

Solid Tumors | Metastatic Disease

Netherlands

Clinical Trials Sponsored by Immunotherapy Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations